0R15 7603.0 -1.7651% 0R1E 7406.0 -1.3848% 0M69 None None% 0R2V 168.75 -0.8811% 0QYR 1341.134 1.2177% 0QYP 392.5 -4.0342% 0LCV 132.52 -0.8084% 0RUK 2940.0 0.616% 0RYA 1742.0 -2.1348% 0RIH 157.95 -0.2211% 0RIH 155.51 -1.5448% 0R1O 171.25 9561.4951% 0R1O None None% 0QFP 8920.4336 76.9927% 0M2Z 296.7062 -0.5009% 0VSO 23.61 -33.6891% 0R1I None None% 0QZI 492.5 -0.1014% 0QZ0 220.0 0.0% 0NZF 859.0151 72.3546%
Last update at 2024-04-25T20:10:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 13477.00M | 12989.00M | 3398.00M | 8426.00M | 5197.00M |
| Minority interest | -9.00000M | -7.00000M | 6.00M | 21.00M | 21.00M |
| Net income | 11836.00M | 11542.00M | 4616.00M | 7882.00M | 5687.00M |
| Selling general administrative | 15260.00M | 12349.00M | 11299.00M | 6942.00M | 7399.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 40640.00M | 38751.00M | 30417.00M | 25827.00M | 25035.00M |
| Reconciled depreciation | 8467.00M | 8521.00M | 6471.00M | 2017.00M | 1765.00M |
| Ebit | 18117.00M | 17924.00M | 476.00M | 12983.00M | 6383.00M |
| Ebitda | 26584.00M | 26445.00M | 6947.00M | 13795.00M | 8148.00M |
| Depreciation and amortization | 8467.00M | 8521.00M | 6471.00M | 812.00M | 1765.00M |
| Non operating income net other | -2596.00000M | -2551.00000M | -5685.00000M | -3048.00000M | -42.00000M |
| Operating income | 18117.00M | 17924.00M | 476.00M | 12983.00M | 6383.00M |
| Other operating expenses | 39240.00M | 37311.00M | 33243.00M | 19898.00M | 25946.00M |
| Interest expense | 2230.00M | 2384.00M | 2280.00M | 1509.00M | 1144.00M |
| Tax provision | 1632.00M | 1440.00M | -1224.00000M | 544.00M | -490.00000M |
| Interest income | 186.00M | 39.00M | 174.00M | 275.00M | 204.00M |
| Net interest income | -2044.00000M | -2384.00000M | -2280.00000M | -1509.00000M | -1144.00000M |
| Extraordinary items | - | - | - | - | -86.00000M |
| Non recurring | 697.00M | 962.00M | 1198.00M | 385.00M | 424.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 1632.00M | 1440.00M | -1224.00000M | 544.00M | -490.00000M |
| Total revenue | 58054.00M | 56197.00M | 45804.00M | 33266.00M | 32753.00M |
| Total operating expenses | 21826.00M | 19865.00M | 17856.00M | 12459.00M | 18228.00M |
| Cost of revenue | 17414.00M | 17446.00M | 15387.00M | 7439.00M | 7718.00M |
| Total other income expense net | -3293.00000M | -3513.00000M | 2922.00M | -4557.00000M | -466.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 11845.00M | 11549.00M | 4622.00M | 7882.00M | 5687.00M |
| Net income applicable to common shares | 11836.00M | 11542.00M | 4616.00M | 7882.00M | 5687.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 138805.00M | 146529.00M | 150565.00M | 89115.00M | 59352.00M |
| Intangible assets | 67439.00M | 75951.00M | 82876.00M | 18649.00M | 21233.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 4401.00M | 4993.00M | 3562.00M | 2354.00M | 1895.00M |
| Total liab | 121518.00M | 131093.00M | 137468.00M | 97287.00M | 67798.00M |
| Total stockholder equity | 17254.00M | 15408.00M | 13076.00M | -8172.00000M | -8446.00000M |
| Deferred long term liab | 2190.00M | 3009.00M | 3646.00M | 1130.00M | 1067.00M |
| Other current liab | 22468.00M | 19817.00M | 17883.00M | 10380.00M | 10385.00M |
| Common stock | 18.00M | 18.00M | 18.00M | 18.00M | 18.00M |
| Capital stock | 18.00M | 18.00M | 18.00M | 18.00M | 18.00M |
| Retained earnings | 4784.00M | 3127.00M | 1055.00M | 4717.00M | 3368.00M |
| Other liab | 31716.00M | 30982.00M | 30401.00M | 18476.00M | 15557.00M |
| Good will | 32156.00M | 32379.00M | 33124.00M | 15604.00M | 15663.00M |
| Other assets | 4834.00M | 4081.00M | 5144.00M | 1913.00M | 1208.00M |
| Cash | 9201.00M | 9746.00M | 8449.00M | 39924.00M | 7289.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 29538.00M | 35194.00M | 28661.00M | 15585.00M | 17239.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 54070.00M | 66938.00M | 77607.00M | 26804.00M | 33021.00M |
| Short term debt | 4136.00M | 12495.00M | 8502.00M | 3753.00M | 5308.00M |
| Short long term debt | 4136.00M | 12495.00M | 8502.00M | 3753.00M | 5308.00M |
| Short long term debt total | 63271.00M | 76684.00M | 86056.00M | 66728.00M | 40310.00M |
| Other stockholder equity | 14651.00M | 15162.00M | 15120.00M | -9311.00000M | -9352.00000M |
| Property plant equipment | 4935.00M | 5110.00M | 5248.00M | 2962.00M | 2883.00M |
| Total current assets | 28463.00M | 27928.00M | 24173.00M | 49519.00M | 16945.00M |
| Long term investments | 241.00M | 277.00M | 293.00M | 93.00M | 1420.00M |
| Net tangible assets | -82341.00000M | -96202.00000M | -102924.00000M | -42425.00000M | -45342.00000M |
| Short term investments | 28.00M | 84.00M | 30.00M | 0.00000M | 772.00M |
| Net receivables | 11254.00M | 9977.00M | 8822.00M | 5428.00M | 5384.00M |
| Long term debt | 59135.00M | 64189.00M | 77554.00M | 62975.00M | 35002.00M |
| Inventory | 3579.00M | 3128.00M | 3310.00M | 1813.00M | 1605.00M |
| Accounts payable | 2934.00M | 2882.00M | 2276.00M | 1452.00M | 1546.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 33.00M | 28.00M | 21.00M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2199.00000M | -2899.00000M | -3117.00000M | -3596.00000M | -2480.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 18.00M | 18.00M | 18.00M | 18.00M | 18.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 4784.00M | 3127.00M | 1055.00M | 4717.00M | 3368.00M |
| Treasury stock | -4594.00000M | -3143.00000M | -2264.00000M | -24504.00000M | -24108.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3381.00M | 1875.00M | 1205.00M | 1158.00M | 141.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 110342.00M | 118601.00M | 126392.00M | 39596.00M | 42407.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 59135.00M | 64189.00M | 77554.00M | 62975.00M | 35002.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -447.00000M | -1398.00000M | 114.00M | 981.00M | -368.00000M |
| Change to liabilities | 2147.00M | 338.00M | 941.00M | -1121.00000M | 190.00M |
| Total cashflows from investing activities | -623.00000M | -2344.00000M | -37557.00000M | 596.00M | -1006.00000M |
| Net borrowings | -12433.00000M | -8414.00000M | -2703.00000M | 25823.00M | 3189.00M |
| Total cash from financing activities | -24803.00000M | -19039.00000M | -11501.00000M | 18708.00M | -14396.00000M |
| Change to operating activities | -264.00000M | -197.00000M | 134.00M | 97.00M | -499.00000M |
| Net income | 11845.00M | 11549.00M | 4622.00M | 7882.00M | 5687.00M |
| Change in cash | -545.00000M | 1297.00M | -31475.00000M | 32635.00M | -2014.00000M |
| Begin period cash flow | 9746.00M | 8449.00M | 39924.00M | 7289.00M | 9303.00M |
| End period cash flow | 9201.00M | 9746.00M | 8449.00M | 39924.00M | 7289.00M |
| Total cash from operating activities | 24943.00M | 22777.00M | 17588.00M | 13324.00M | 13427.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 8467.00M | 8521.00M | 6471.00M | 2017.00M | 1765.00M |
| Other cashflows from investing activities | 519.00M | -159.00000M | -36873.00000M | 167.00M | 167.00M |
| Dividends paid | -10043.00000M | -9261.00000M | -7716.00000M | -6366.00000M | -5580.00000M |
| Change to inventory | -686.00000M | -142.00000M | -40.00000M | -231.00000M | -226.00000M |
| Change to account receivables | -1455.00000M | -1321.00000M | -929.00000M | -74.00000M | -591.00000M |
| Sale purchase of stock | -1487.00000M | -934.00000M | -978.00000M | -629.00000M | -12014.00000M |
| Other cashflows from financing activities | 1160.00M | -674.00000M | -333.00000M | -552.00000M | -104.00000M |
| Change to netincome | 2646.00M | 4029.00M | 6389.00M | 4754.00M | 6677.00M |
| Capital expenditures | 695.00M | 787.00M | 798.00M | 552.00M | 638.00M |
| Change receivables | -1455.00000M | -1321.00000M | -929.00000M | -74.00000M | -591.00000M |
| Cash flows other operating | 1979.00M | -197.00000M | 134.00M | 97.00M | -75.00000M |
| Exchange rate changes | - | -97.00000M | -5.00000M | 7.00M | -39.00000M |
| Cash and cash equivalents changes | -483.00000M | 1297.00M | -31475.00000M | 32635.00M | -2014.00000M |
| Change in working capital | -258.00000M | -1322.00000M | 106.00M | -1329.00000M | -1126.00000M |
| Stock based compensation | 671.00M | 692.00M | 753.00M | 430.00M | 421.00M |
| Other non cash items | 6149.00M | 4235.00M | 7961.00M | 3624.00M | 6256.00M |
| Free cash flow | 24248.00M | 21990.00M | 16790.00M | 12772.00M | 12789.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABBV AbbVie Inc |
-0.51 0.30% | 167.29 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| LLY Eli Lilly and Company |
-7.33 1.00% | 724.87 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
-1.71 1.15% | 146.82 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| MRK Merck & Company Inc |
3.70 2.91% | 130.70 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| RHHVF Roche Holding AG Participation |
-3.794 1.57% | 237.72 | 17.21 | 12.08 | 3.61 | 7.37 | 4.15 | 13.04 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 1954 |
| Mr. Robert A. Michael | Vice Chairman & Pres | 1970 |
| Ms. Laura J. Schumacher | Vice Chairman of External Affairs & Chief Legal Officer | 1963 |
| Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer | 1969 |
| Mr. Scott T. Reents | Exec. VP & CFO | 1967 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP of Operations | 1963 |
| Dr. Thomas J. Hudson | Sr. VP of R&D and Chief Scientific Officer | 1962 |
| Ms. Elizabeth Shea | VP of Investor Relations | NA |
| Mr. Perry C. Siatis | Exec. VP, Gen. Counsel & Sec. | NA |
| Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | 1966 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...